systematic review | Q1504425 |
scholarly article | Q13442814 |
meta-analysis | Q815382 |
P2093 | author name string | S. Murray | |
D. Bafaloukos | |||
P. Kosmidis | |||
H. Linardou | |||
I. J. Dahabreh | |||
P2860 | cites work | Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials | Q24625201 |
Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
Measuring inconsistency in meta-analyses | Q27860655 | ||
Meta-analysis in clinical trials | Q27860779 | ||
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
Lung cancer in never smokers: a review | Q28287500 | ||
EGFR antagonists in cancer treatment | Q29616740 | ||
Interaction revisited: the difference between two estimates | Q29619619 | ||
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 | ||
Why the epidermal growth factor receptor? The rationale for cancer therapy | Q34803451 | ||
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | Q34986549 | ||
Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
Controlling the risk of spurious findings from meta-regression. | Q35782230 | ||
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort | Q36048238 | ||
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis | Q36311791 | ||
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors | Q36472193 | ||
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 | ||
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status | Q36950271 | ||
EGFR FISH versus mutation: different tests, different end-points. | Q37119476 | ||
Molecular genetics of lung cancer in people who have never smoked | Q37206476 | ||
Issues in using progression-free survival when evaluating oncology products | Q37231532 | ||
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 | ||
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. | Q37502708 | ||
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer | Q37661173 | ||
Population-based differences in treatment outcome following anticancer drug therapies. | Q37686610 | ||
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
Ecological bias, confounding, and effect modification | Q38632643 | ||
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy | Q43920708 | ||
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer | Q44219909 | ||
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer | Q44485092 | ||
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database | Q45717160 | ||
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study | Q46213605 | ||
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib | Q46305423 | ||
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study | Q46380513 | ||
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 | ||
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study | Q46585165 | ||
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | Q46624747 | ||
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. | Q46638033 | ||
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients | Q46730203 | ||
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay | Q46731569 | ||
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? | Q46776120 | ||
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. | Q51787477 | ||
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. | Q53569591 | ||
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis | Q56588945 | ||
Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments | Q57542907 | ||
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens | Q59629307 | ||
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial | Q62992066 | ||
Improved tests for a random effects meta-regression with a single covariate | Q73855792 | ||
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 | ||
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib | Q80250628 | ||
Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer | Q80288783 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
biomarker | Q864574 | ||
gene dosage | Q1465102 | ||
systematic review | Q1504425 | ||
meta-analysis | Q815382 | ||
P304 | page(s) | 545-52 | |
P577 | publication date | 2010-09-08 | |
2011-03-01 | |||
P1433 | published in | Annals of Oncology | Q326122 |
P1476 | title | EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer | |
P478 | volume | 22 |